The investigation by Levi & Korsinsky into Harmony Biosciences for potential securities law violations is significant, as it follows a report by Scorpion Capital that raised concerns about the company's drug, Wakix. This could lead to legal challenges and affect investor confidence, likely impacting the stock negatively in the short term.